STOCK TITAN

Leap Therapeutics to Participate at Piper Sandler 32nd Annual Virtual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Leap Therapeutics, Inc. (Nasdaq:LPTX) announced that CEO Douglas E. Onsi will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1-3, 2020. A pre-recording of the chat is accessible on the company’s investors page, with a replay available for 90 days. Leap focuses on developing targeted and immuno-oncology therapeutics, with DKN-01 as their lead candidate, currently in clinical trials for various cancers. The company collaborates with BeiGene for DKN-01's development in Asia, Australia, and New Zealand.

Positive
  • None.
Negative
  • None.

CAMBRIDGE, Mass., Nov. 23, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference, being held on December 1-3, 2020.

A pre-recording of the fireside chat is currently available on the Investors page of the company's website at https://investors.leaptx.com/. A replay of the event will be available for 90 days.

About Leap Therapeutics

Leap Therapeutics (Nasdaq:LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap has formed a strategic partnership with BeiGene, Ltd. for the rights to develop DKN-01 in Asia (excluding Japan), Australia, and New Zealand. For more information about Leap Therapeutics, visit http://www.leaptx.com or our public filings with the SEC that are available via EDGAR at http://www.sec.gov or via https://investors.leaptx.com/ .

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. These statements include statements regarding expectations with respect to the development and advancement of DKN-01, including the initiation, timing and design of future studies, enrollment in future studies, potential for the receipt of future option exercise, milestones or royalty payments from BeiGene, and other future expectations, plans and prospects. Although Leap believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from our expectations. Such risks and uncertainties include, but are not limited to: that the initiation, conduct, and completion of clinical trials, laboratory operations, manufacturing campaigns, and other studies may be delayed, adversely affected, or impacted by COVID-19 related issues, the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for financing; the outcome, cost, and timing of our product development activities and clinical trials; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; our ability to obtain and maintain regulatory approval of our drug product candidates; the size and growth potential of the markets for our drug product candidates; our ability to continue obtaining and maintaining intellectual property protection for our drug product candidates; and other risks. Detailed information regarding factors that may cause actual results to differ materially will be included in Leap Therapeutics' periodic filings with the SEC, including Leap's Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as filed with the SEC on March 16, 2020. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

CONTACT:

Douglas E. Onsi
President & Chief Executive Officer
Leap Therapeutics, Inc.
617-714-0360
donsi@leaptx.com

Heather Savelle
Investor Relations
Argot Partners
212-600-1902
heather@argotpartners.com

Leap Therapeutics logo (PRNewsfoto/LEAP Therapeutics)

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/leap-therapeutics-to-participate-at-piper-sandler-32nd-annual-virtual-healthcare-conference-301178545.html

SOURCE Leap Therapeutics, Inc.

FAQ

What conference will Leap Therapeutics participate in during December 2020?

Leap Therapeutics will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1-3, 2020.

Who is representing Leap Therapeutics at the Piper Sandler conference?

Douglas E. Onsi, the President and CEO of Leap Therapeutics, will represent the company.

Where can I find the replay of Leap Therapeutics' fireside chat?

The replay of Leap Therapeutics' fireside chat will be available on their investors page for 90 days.

What is DKN-01 and which cancers is it targeting?

DKN-01 is Leap Therapeutics' lead candidate, a humanized monoclonal antibody targeting Dickkopf-1, currently in clinical trials for esophagogastric, hepatobiliary, gynecologic, and prostate cancers.

What partnership does Leap Therapeutics have for DKN-01?

Leap Therapeutics has a strategic partnership with BeiGene for the development rights of DKN-01 in Asia, Australia, and New Zealand.

Leap Therapeutics, Inc.

NASDAQ:LPTX

LPTX Rankings

LPTX Latest News

LPTX Stock Data

114.03M
38.26M
17.31%
41.64%
1.89%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CAMBRIDGE